Is the EU's Biosimilar Wave Faltering?

Drug Development Is the EU's Biosimilar Wave Faltering?

20.09.2021Editor: Alexander Stark

Data and analytics company Global Data has predicted that the arrival of biosimilar therapies in the EU will continue to fall in the coming years following a wave pattern that has been occurring since 2006.

Related Company

GlobalData

London/UK — Global Data’s senior drugs database analyst Quentin Horgan notes that EU biosimilar development is currently in the downward trajectory of a wave that peaked in 2018, and it is likely that there are similar waves happening in the US and APAC markets.

Horgan comments: “Biosimilars come in waves of development and approval. In the peaks of these waves, we see a large surge of biosimilars in late-stage pipeline development alongside increases in the approvals of biosimilar products. These waves often coincide with the expiry of innovator biologics, as the loss of market exclusivity within a region provides biosimilar developers with a greater opportunity to enter a market and removes legal and patent barriers to their entry.”

The EU biosimilar wave shows an average increase of 69% in approvals between 2013 and 2018.
(Source: Global Data Pharma Intelligence Center)

Horgan continues: “The EU experienced this biosimilar wave ahead of regions such as the US and Asia-Pacific because the EU created the first biosimilar-specific approval pathway in 2005, and subsequently approved the first biosimilar somatropin in 2006. In addition, the region has had a strong uptake of biosimilars over brand biologics and, therefore, has one of the biggest biosimilar markets.”

The EU biosimilar wave shows an average increase of 69 percent in approvals between 2013 and 2018, with peak approvals of 13 in 2018. This corresponds with an earlier peak of biosimilar expirations in 2017, with twelve drugs expiring. The EU biosimilar wave subsequently slowed down as biosimilar approvals declined in 2019 and 2020 Horgan concludes: “We can use this wave pattern to predict a further fall in biosimilar development and approvals.”

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:47644662)

Drug Development Is the EU's Biosimilar Wave Faltering?

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes